Connecting Genomic Alterations to Cancer Biology with Proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium

Overview

Journal Cancer Discov

Specialty Oncology

Date 2013 Oct 15

PMID 24124232

Citations 151

Authors

Matthew J Ellis

Michael Gillette

Steven A Carr

Amanda G Paulovich

Richard D Smith

Karin K Rodland

R Reid Townsend

Christopher Kinsinger

Mehdi Mesri

Henry Rodriguez

Daniel C Liebler

Affiliations

Soon will be listed here.

Abstract

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.

Citing Articles

Advancements in proteogenomics for preclinical targeted cancer therapy research.

Suo Y, Song Y, Wang Y, Liu Q, Rodriguez H, Zhou H Biophys Rep. 2025; 11(1):56-76.

PMID: 40070661 PMC: 11891078. DOI: 10.52601/bpr.2024.240053.

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Schmauch B, Cabeli V, Domingues O, Le Douget J, Hardy A, Belbahri R iScience. 2025; 28(1):111638.

PMID: 39868035 PMC: 11758823. DOI: 10.1016/j.isci.2024.111638.

Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy.

Bai W, Xu J, Gu W, Wang D, Cui Y, Rong W Nat Commun. 2025; 16(1):474.

PMID: 39774694 PMC: 11707192. DOI: 10.1038/s41467-024-55481-7.

Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer.

Perez J, Duda J, Ryu J, Shetty M, Mehta S, Jagtap P Sci Rep. 2025; 15(1):813.

PMID: 39755759 PMC: 11700199. DOI: 10.1038/s41598-024-84874-3.

Accumulation of microtubule-associated protein tau promotes hepatocellular carcinogenesis through inhibiting autophagosome-lysosome fusion.

Liu X, Hao Z, He H, Wang X, Wang W, Shu X Mol Cell Biochem. 2024; .

PMID: 39718681 DOI: 10.1007/s11010-024-05193-9.

References

Zhang G, Fang B, Liu R, Lin H, Kinose F, Bai Y . Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res. 2010; 10(1):305-19. PMC: 3050523. DOI: 10.1021/pr1006203. View

Goldstein T, Paull E, Ellis M, Stuart J . Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res. 2013; 19(12):3114-20. PMC: 3686839. DOI: 10.1158/1078-0432.CCR-12-2093. View

Mertins P, Udeshi N, Clauser K, Mani D, Patel J, Ong S . iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012; 11(6):M111.014423. PMC: 3433912. DOI: 10.1074/mcp.M111.014423. View

Ellis M, Perou C . The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013; 3(1):27-34. PMC: 3553590. DOI: 10.1158/2159-8290.CD-12-0462. View

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

Addona T, Abbatiello S, Schilling B, Skates S, Mani D, Bunk D . Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27(7):633-41. PMC: 2855883. DOI: 10.1038/nbt.1546. View

Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M . Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012; 72(10):2501-11. PMC: 4641440. DOI: 10.1158/0008-5472.CAN-11-3015. View

Liu Q, Halvey P, Shyr Y, Slebos R, Liebler D, Zhang B . Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation. Mol Cell Proteomics. 2013; 12(7):1900-11. PMC: 3708174. DOI: 10.1074/mcp.M112.025783. View

Wolf-Yadlin A, Hautaniemi S, Lauffenburger D, White F . Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A. 2007; 104(14):5860-5. PMC: 1851582. DOI: 10.1073/pnas.0608638104. View

10.

Rudnick P, Clauser K, Kilpatrick L, Tchekhovskoi D, Neta P, Blonder N . Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics. 2009; 9(2):225-41. PMC: 2830836. DOI: 10.1074/mcp.M900223-MCP200. View

11.

Razavi M, Frick L, LaMarr W, Pope M, Miller C, Anderson N . High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res. 2012; 11(12):5642-9. DOI: 10.1021/pr300652v. View

12.

Shi T, Fillmore T, Sun X, Zhao R, Schepmoes A, Hossain M . Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A. 2012; 109(38):15395-400. PMC: 3458402. DOI: 10.1073/pnas.1204366109. View

13.

Halvey P, Ferrone C, Liebler D . GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res. 2012; 11(7):3908-13. PMC: 3400422. DOI: 10.1021/pr300161j. View

14.

Picotti P, Aebersold R . Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012; 9(6):555-66. DOI: 10.1038/nmeth.2015. View

15.

Chen Y, Gruidl M, Remily-Wood E, Liu R, Eschrich S, Lloyd M . Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res. 2010; 9(8):4215-27. PMC: 2924816. DOI: 10.1021/pr1005197. View

16.

Michalski A, Damoc E, Lange O, Denisov E, Nolting D, Muller M . Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol Cell Proteomics. 2011; 11(3):O111.013698. PMC: 3316736. DOI: 10.1074/mcp.O111.013698. View

17.

Gillette M, Carr S . Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2012; 10(1):28-34. PMC: 3943160. DOI: 10.1038/nmeth.2309. View

18.

Gallien S, Duriez E, Crone C, Kellmann M, Moehring T, Domon B . Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics. 2012; 11(12):1709-23. PMC: 3518128. DOI: 10.1074/mcp.O112.019802. View

19.

Liu H, Sadygov R, Yates 3rd J . A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004; 76(14):4193-201. DOI: 10.1021/ac0498563. View

20.

MacLean B, Tomazela D, Shulman N, Chambers M, Finney G, Frewen B . Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010; 26(7):966-8. PMC: 2844992. DOI: 10.1093/bioinformatics/btq054. View